Oxford Gene Technology Grants Microarray Licence to BF-BIOlabs
News Sep 29, 2008
Oxford Gene Technology (OGT) and BF-BIOlabs have announced the completion of a licensing agreement granting BF-BIOlabs access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.
The granted licence will enable BF-BIOlabs to sell arrays and provide services that include the design and production of custom-made microarrays for gene-identification, single nucleotide polymorphisms (SNP) and gene expression analysis.
Susan Sutton, Vice President Licensing (North America and Europe) at OGT, said: “OGT continues to grow its microarray licensee portfolio in Europe and this in turn will enable companies to expand their business activities and make microarray technology more accessible.”
BF-BIOlabs designs and produces custom-made microarrays for gene-identification, SNP, and gene-expression analysis, using specialized microarray production processes to achieve optimal specificity and sensitivity. In addition, BF-BIOlabs offers a full service for microarray experiments, chip readout and data analysis.
The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE